Here, we describe a method to selectively alter gene expressions in the choroid plexus while avoiding any impact in other brain areas.
The choroid plexus (ChP) serves as a critical gateway for immune cell infiltration into the central nervous system (CNS) under both physiological and pathological conditions. Recent research has shown that regulating ChP activity may offer protection against CNS disorders. However, studying the biological function of the ChP without affecting other brain regions is challenging due to its delicate structure. This study presents a novel method for gene knockdown in ChP tissue using adeno-associated viruses (AAVs) or cyclization recombination enzyme (Cre) recombinase protein consisting of TAT sequence (CRE-TAT). The results demonstrate that after injecting AAV or CRE-TAT into the lateral ventricle, the fluorescence was exclusively concentrated in the ChP. Using this approach, the study successfully knocked down the adenosine A2A receptor (A2AR) in the ChP using RNA interference (RNAi) or Cre/locus of X-overP1 (Cre/LoxP) systems, and showed that this knockdown could alleviate the pathology of experimental autoimmune encephalomyelitis (EAE). This technique may have important implications for future research on the ChP’s role in CNS disorders.
The choroid plexus (ChP) was often thought to help maintain brain functional homeostasis by secreting cerebrospinal fluid (CSF) and brain-derived neurotrophic factor (BDNF)1,2. Increasing research over the last three decades has revealed that the ChP represents a distinct pathway for immune cell infiltration into the central nervous system (CNS).
The tight junctions (TJs) of the ChP, composed of a monolayer ChP epithelium, maintain immunological homeostasis by preventing macromolecules and immune cells from entering the brain3. However, under certain pathological conditions, the ChP tissue detects and responds to danger-associated molecular patterns (DAMPs) in the CSF and blood, leading to abnormal immune infiltration and brain dysfunction4,5. Despite its critical role, the ChP's small size and unique location in the brain make it difficult to study its function without affecting other brain regions. Therefore, manipulating gene expression specifically in the ChP is an ideal approach to understanding its function.
Initially, cyclization recombination enzyme (Cre) transgenic lines, which express Cre under the control of promoters specific to genes expressed in the ChP, were commonly used to delete target genes by breeding with floxed candidate genes6,7,8. For example, the transcription factor Forkhead box J1 (FoxJ1) is exclusively expressed in the ChP epithelium of the prenatal mouse brain7. Thus, the FoxJ1-Cre line was often used to delete genes located in the ChP6,9. However, the success of this strategy relies heavily on the specificity of the promoter. It was gradually discovered that the FoxJ1 expression pattern was not distinctive enough, as FoxJ1 was also present in ciliated epithelial cells in other parts of the brain and peripheral system7. To overcome this limitation, intra-cerebroventricular (ICV) injection of Cre recombinase was performed to deliver recombinase into the ventricles of floxed transgenic lines. This strategy showed high specificity, as evidenced by the presence of tdTomato fluorescence solely in the ChP tissue10,11. However, this method is still limited by the availability of floxed transgenic mouse lines. To address this issue, researchers have employed ICV injection of adeno-associated virus (AAV) to achieve ChP-specific knockdown or the overexpression of target genes12,13. A comprehensive evaluation of different AAV serotypes for ChP infection revealed that AAV2/5 and AAV2/8 exhibit strong infection abilities in the ChP, while not infecting other brain regions. However, AAV2/8 was found to infect the ependyma surrounding ventricles, whereas the AAV2/5 group showed no infection14. This method has the advantage of overcoming the limitations of acquiring floxed transgenic animals.
This article describes a step-by-step protocol for gene knockdown in the ChP using two methods: ICV of AAV2/5 carrying shRNA of the adenosine A2A receptor (A2AR) and Cre recombinase protein consisting of TAT sequence (CRE-TAT) recombinase to achieve ChP-specific knockdown of A2AR. The study findings suggest that knocking down A2AR in the ChP can alleviate experimental autoimmune encephalomyelitis (EAE). This detailed protocol provides useful guidance for ChP function studies and the specific knockdown of genes in the ChP.
All animal procedures described in this study were conducted in accordance with the guidelines outlined in the NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at Wenzhou Medical University.
1. Animals
2. ChP-specific knockdown of A2ARs with AAV2/5-shRNA
3. ChP-specific knockdown of A2AR with a Cre/locus of X-overP1 (Cre/LoxP) system
NOTE: The following procedures can be achieved using the method described previously. Refer to steps 2.1-2.11 for detailed injection methods.
4. Transcardial perfusion in mice
5. Frozen tissue sectioning and staining
6. EAE induction
NOTE: Perform EAE induction after 2 weeks of the shRNA or CRE-TAT recombinase injection11.
7. Neurological deficit score
8. Hematoxylin-eosin (H&E) staining
9. Quantitative polymerase chain reaction (qPCR) analysis
ChP-specific A2AR knockdown by ICV injection of AAV2/5-shRNA or CRE-TAT
The role of A2AR in the ChP as a powerful regulator of neural information in EAE pathogenesis remains unclear. Knocking down ChP-specific A2AR expression could shed light on the A2AR regulatory effects on the central immune system in EAE and other nervous system inflammations. This study used ICV injection of CRE-TAT to decrease A2AR expression in the ChP of A2ARflox/flox mice. To ensure ChP specificity, we first injected CRE-TAT into the lateral ventricles of Rosa-LSL (Lox-StoP-Lox)-tdTomato (Ai9) mice. The images indicate that the spontaneous tdTomato fluorescence was restricted to the ChP tissue (Figure 2). Similarly, the study administered AAV2/5-CMV-A2AR-shRNA-CMV-enhanced green fluorescent protein (EGFP) into C57BL/6 mice and found that the EGFP fluorescence was limited to the epithelial cell layer of the ChP and did not infect the surrounding parenchymal cells near the lateral ventricles (Figure 3).
EAE induction with MOG35-55
To induce stable EAE, mice were subcutaneously injected with an emulsion consisting of MOG35-55 and CFA, followed by intraperitoneal injection of PT on days 0 and 2 after immunization (Figure 4). The Clinical Symptom Scale was used to evaluate EAE scores daily, based on the tail and limb condition. The onset of EAE was defined as the first day with an EAE score ≥1, while the duration between onset and peak EAE scores was called the progressive stage.
ChP-specific A2AR knockdown alleviates EAE pathology
To investigate the involvement of the A2AR signal in EAE pathology, the study employed a ChP-specific A2AR knockdown. The study specifically knocked down A2AR in the ChP using ICV injection of CRE-TAT or AAV2/5-A2AR-shRNA. At 2 weeks after knockdown, EAE was induced by MOG35-55 immunization. The results showed that, compared to the control group, mice with A2AR knockdown developed milder EAE pathology, as evidenced by lower scores and a reduced infiltration of immune cells in the spinal cord (Figure 5A,B,E,F). In addition, five EAE-induced mice from each group at day 20 following MOG35-55 immunization were randomly selected. After perfusion with PBS, the ChPs were isolated for RNA extraction and qPCR. The qPCR analysis showed that the mRNA levels of A2AR were obviously decreased in the AAV2/5-shRNA (A2AR-Kd) and CRE-TAT groups, compared to each control (Figure 5C,D).
Figure 1: Anatomical localization of the lateral ventricle injection site. (A) A schematic diagram showing the point of virus injection. (B) The injection site of the lateral ventricle is located 0.58 mm below the bregma and 1.1 mm lateral to the sagittal suture, as indicated by the red dot. (C) An image showing the site of virus injection on a mouse. Please click here to view a larger version of this figure.
Figure 2: Localization of tdTomato fluorescence in the ChP. (A,B) Representative image of Rosa-LSL (Lox-StoP-Lox)-tdTomato mice treated with ICV injection of CRETAT. At 2 weeks later, the tdTomato autofluorescence was specifically localized to the ChP tissue (n = 3/group). (C,D) The merged images of the tdTomato autofluorescence and DAPI. Please click here to view a larger version of this figure.
Figure 3: Representative images of C57BL/6 mice taken 2 weeks after ICV injection of AAV2/5-scramble-EGFP or AAV2/5-shRNA-EGFP. (A,B) The representative images of mice injected with AAV2/5-scramble-EGFP (n = 3/group). (C,D) The representative images of mice injected with AAV2/5-shRNA-EGFP (n = 3/group). Please click here to view a larger version of this figure.
Figure 4: Induction of the EAE model. (A) Firstly, the MOG antigen emulsion is subcutaneously injected into four different locations (neck, back, left and right hips), which are denoted by red dots. (B) PT is intraperitoneally injected at the time of immunization and repeated 2 days later. Please click here to view a larger version of this figure.
Figure 5: ChP-specific knockdown of A2AR alleviated EAE pathology. (A) ChP-specific knockdown of A2AR in A2ARflox/flox mice, achieved through ICV injection of CRE-TAT, led to decreased EAE clinical scores (n = 6-7/group). Statistical analysis was performed using twoway RM ANOVA followed by Sidak's multiple comparison test. (B) ChP-specific knockdown of A2AR in wild-type (WT) mice, achieved with ICV injection of AAV2/5-shRNA, decreased EAE clinical scores (n = 7-8/group). Statistical analysis was performed using twoway RM ANOVA followed by Sidak's multiple comparison test. (C,D) Results of the qPCR analysis of A2AR mRNA levels in ChP tissue (n = 5/group). Statistical analysis was performed using an unpaired t-test. (E,F) H&E staining. ChP-specific A2AR knockdown attenuated immune cell infiltration into the spinal cord. Statistical significance is represented as ###p < 0.001, **p < 0.01, and ***p < 0.001. Please click here to view a larger version of this figure.
The research presented two distinct approaches for the targeted knockdown of ChP genes. The first approach involved the ICV injection of CRE-TAT, which contains Cre recombinase, into A2ARflox/flox mice. The second approach entailed ICV injection of AAV2/5 carrying shRNA of A2AR. By utilizing these two strategies, the work achieved the selective knockdown of A2AR within the ChP and was able to demonstrate the protective effects of inhibiting A2AR signaling in the ChP on EAE pathology. Of note, this protocol includes two crucial steps. Firstly, the stereotaxic localization operation is essential, and significant deviation from the suggested coordinates may result in random failures. Secondly, the volume of the injected virus is critical, as it has been found that injecting less than 1 µL of virus (~6 x 1012) also has a certain chance of failure. This is possibly due to the need for an adequate amount of virus particles for sufficient infection.
Using the Cre/LoxP system did not allow observation of the precise distribution of CRE-TAT recombinase in the brain following ICV injection. As a result, the study utilized Rosa-LSL (Lox-StoP-Lox)-tdTomato mice to track the distribution of CRE-TAT using the autofluorescence of the tdTomato protein. The tdTomato fluorescence was exclusively located in ChP tissues 2 weeks after injecting CRE-TAT intracerebroventricularly, indicating that the recombinase was primarily absorbed by the ChP. Next, CRE-TAT was administered to A2ARflox/flox mice, and a decrease in A2AR mRNA levels was observed in the ChP tissue. This targeted knockdown strategy was used to investigate the role of corticosteroid signaling in the ChP in mediating psychological stress17. Alternatively, the research used AAV2/5 to deliver shRNA designed to target ChP genes. Previous studies have evaluated the infection ability of different serotypes of AAVs and lentiviruses in ChP tissue and found that AAV2/5 and AAV2/8 were the most effective14. The study revealed that AAV2/5 was capable of infecting the ChP specifically without causing obvious infections in other brain regions. These two methods are less laborious than classical knockout strategies that require two transgenic lines (Cre and Flox lines)6,18. One limitation of this study is the absence of a gain-of-function experiment with gene overexpression. However, a possible approach to achieve this would be to clone the full cDNA and package it into the AAV2/5 virus, which would be administered via ICV infection. In a previous study, overexpression of NKCC1 in the ChP using AAV2/5 was found to promote CSF clearance and reduce ventriculomegaly in vivo9. It is important to note that either the AAV2/5 or Cre/LoxP strategy have their own advantage. The ICV injection of CRE-TAT into transgenic mice ensures high knockdown efficiency, as the target gene is directly deleted from the DNA of the cells. However, this method depends on floxed mice production and breeding. On the other hand, the ICV injection of AAV2/5 avoids the time-consuming process of breeding transgenic mice. However, the knockdown efficiency of this method largely depends on the performance of the designed shRNA. Therefore, researchers can choose a suitable method based on their experimental conditions.
Multiple sclerosis (MS) is an autoimmune disease that causes inflammation and demyelination of white matter in the CNS19. To study the pathological mechanisms of MS, researchers have used an EAE model that simulates the disease's symptoms, such as demyelination and immune infiltration. This model is considered ideal for understanding MS. In 2009, it was discovered that immune cells infiltrate the CNS through the ChP, which is a key route for immune cell entry in MS pathology. The "first wave" of immune cells enters CSF through the ChP, followed by the "second wave", which enters the brain parenchyma through the BBB20. The "first wave" of immune cells promotes inflammation and accelerates BBB leakage, so inhibiting immune infiltration at the ChP could be useful for early intervention in MS. Chemokines and adhesion molecules regulate the gating activity of ChP, controlling the ability of lymphocytes to infiltrate across it21,22,23.
Previous studies used whole-body knockout or pharmacological technology (such as neutralizing antibodies) to investigate signaling molecules in the ChP, but these methods did not accurately define their biological function in the MS pathological process. In a recent study, researchers knocked down A2AR, located in the ChP of A2ARflox/flox mice, and found that EAE scores and immune infiltration were significantly reduced11. This study confirms the role of A2AR signaling in the ChP during EAE pathology and demonstrates that ChP-specific knockdown methods are useful tools for studying ChP function in CNS pathologies.
In conclusion, the ChP-specific manipulation protocol is an ideal tool to explore the biology function of the ChP involved in degenerative diseases in the CNS, such as Parkinson's disease, Alzheimer's disease, MS, and so on.
The authors have nothing to disclose.
We gratefully acknowledge the support of the National Natural Science Foundation of China (Grant No. 31800903, awarded to W. Zheng) and the Wenzhou Science and Technology Project (no. Y2020426, awarded to Y. Y. Weng) for this work.
A2ARflox/flox mice | State Key Laboratory of Ophthalmology, Optometry and Visual Science, Wenzhou Medical University | ||
AAV2/5-A2AR-ShRNA virus | Shanghai Heyuan Biotechnology Co. LTD | pt-4828 | |
antifade mounting medium | Beyotime Biotechnology | 0100-01 | |
borosilicate glass capillary | Beijing Meiyaxian Technology Co. Ltd | B100-50-10 | |
brain stereotaxic apparatus | RWD, Shenzhen | 69100 | |
C57BL/6 mice | Beijing Vital Charles River Laboratory Animal Technology Company | ||
CRE-TAT recombinase | Millipore | SCR508 | |
DAPI | Absin | B25A031 | |
frozen slicing machine | Leica | CM1950 | |
H37Ra | Becton Dickinson and company | 231141 | |
Hamilton syringe | Hamilton, American | P/N: 86259 | |
Incomplete Freunds adjuvant | Sigma | F5506 | |
Laser confocal microscope | Zeiss | LSM900 | |
MOG35-55 | Suzhou Qiangyao Biotechnology Co., LTD | 4010006243 | |
OCT glue | Epredia | 6502p | |
paraformaldehyde | Chengdu Kelong Chemical Reagent Company | 30525-89-4 | |
pentobarbital sodium | Boyun Biotech | PC13003 | |
Pipette gun | Eppendorf | N45014F | |
PrimeScript 1st Strand cDNA Synthesis Kit | Takara | 6110A | |
Real- Time PCR System | BioRad | CFX96 | |
Rosa-LSL (Lox-StoP-Lox)-tdTomato mice | Jackson Laboratory | ||
sucrose | Sangon Biotech | A502792-0500 | |
super high speed homogenizer | IKA | 3737025 | |
Trizol | Invitrogen | 15596026 | |
xylene solution | Chengdu Kelong Chemical Reagent Company | 1330-20-7 |